Table 1.
Patient characteristics
| Variable | Study group (n = 91) |
|---|---|
| Sex | |
| Male | 61 (67 %) |
| Female | 30 (33 %) |
| Age (years) | |
| Median | 62 |
| Mean ± SD | 62.5 ± 7.9 |
| Range | 38–78 |
| Smoking status (pack-years) | |
| Median | 30 |
| Mean ± SD | 31.4 ± 9.5 |
| Non-smokers | 5 (5.5 %) |
| Current smokers | 65 (71.4 %) |
| Former Smokers | 20 (22 %) |
| No data | 1 (1.1 %) |
| Histopathological diagnosis | |
| Adenocarcinoma | 46 (50.5 %) |
| Squamous cell carcinoma | 14 (15.4 %) |
| Large cell carcinoma | 16 (17.6 %) |
| NOS (not otherwise specified) | 15 (16.5 %) |
| Stage of disease | |
| IIIB | 28 (30.8 %) |
| IV | 63 (69.2 %) |
| Performance status | |
| PS = 0 | 12 (13.2 %) |
| PS ≥ 1 | 79 (86.8 %) |
| Weight loss before CTH | |
| Yes | 39 (42.9 %) |
| No | 43 (47.2 %) |
| No data | 9 (9.9 %) |
| Anemia before CTH | |
| Yes | 59 (64.8 %) |
| No | 32 (35.2 %) |
| Side effect after I line CTH | |
| Yes | 59 (64.8 %) |
| No | 24 (26.4 %) |
| No data | 8 (8.8 %) |
| Subsequent lines of treatment | |
| Yes | 51 (56.1 %) |
| No | 40 (43.9 %) |
| Second-line CTH (monotherapy) | 51 (56.1 %) |
| ERL | 12 (13.2 %) |
| PEM | 26 (28.6 %) |
| DCX | 13 (14.3 %) |
| Third-line CTH (monotherapy) | 15 (16.5 %) |
| ERL | 5 (5.5 %) |
| PEM | 6 (6.6 %) |
| DCX | 4 (4.4 %) |
ERL erlotinib, DCX docetaxel, PEM pemetrexed